Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 3.07
Day High 3.13
Open:3.13
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Resverlogix Corp clinical stage biotechnology company. Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
GlobeNewswire - Thu Jan 31, 4:59PM CST
GlobeNewswire - CMTX
Thu Jan 31, 4:59PM CST
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 2.2 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") at a price of $3.00 per unit for gross proceeds of approximately $6.6 million (US$5 million). Each unit was comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant is exercisable at a price of $3.21 per share for a period of three years from the closing of the private placement. The units are subject to a four-month hold period.
Hemostemix Provides Highlights of 2018 Accomplishments
GlobeNewswire - Thu Jan 17, 7:29AM CST
GlobeNewswire - CMTX
Thu Jan 17, 7:29AM CST
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on accomplishments and milestones that it has achieved in 2018. The past twelve months has seen a transformation in the Company, with a significant amount of progress made on multiple fronts, including patient and site enrollment for the current Phase II clinical trial for critical limb ischemia, manufacturing optimization, research and development, and enhancing its management and scientific team. All of the Company's efforts in 2018 have furthered the core goal of achieving commercialization of its technology and furtherance of its research and development into new indications for additional clinical trials.
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
GlobeNewswire - Wed Dec 19, 7:30AM CST
GlobeNewswire - CMTX
Wed Dec 19, 7:30AM CST
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed an eighth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk cardiovascular disease (CVD) patients and recommended the study continue without modification. The DSMB reviewed available safety data and commented that no safety concerns were identified. Resverlogix, the clinical steering committee, and all investigators remain blinded to the trial data.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 3.04 +0.99% increase
on 02/19/19
Period Open:3.23
Price movement based on the high, low and last over the given period.
3.28 -6.40% decrease
on 02/04/19
-0.16 (-4.95%) decrease
since 01/18/19
3-Month 2.94 +4.42% increase
on 12/10/18
Period Open:3.21
Price movement based on the high, low and last over the given period.
3.49 -12.03% decrease
on 01/07/19
-0.14 (-4.36%) decrease
since 11/20/18
52-Week 1.11 +176.58% increase
on 05/31/18
Period Open:1.63
Price movement based on the high, low and last over the given period.
4.31 -28.77% decrease
on 09/07/18
+1.44 (+88.34%) increase
since 02/20/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).